Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-targeted CAR-T cells (First Affiliated Hospital of Soochow University)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-targeted CAR-T cells (First Affiliated Hospital of Soochow University) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets the CD19 antigen, a protein consistently expressed on the surface of B-cell non-Hodgkin lymphoma (B-NHL) cells. Once re-infused into the patient, these engineered T cells recognize and bind to CD19-positive tumor cells, leading to T-cell activation, proliferation, and the subsequent lysis of the malignant cells. This specific CAR-T product is currently being investigated in Phase 2 clinical trials, particularly in combination with the XPO1 inhibitor selinexor, to evaluate its safety and efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Other names
- CAR-T-The First Affiliated Hospital of Soochow University-B-cell non-Hodgkin lymphomaCD19 CAR-TCD-19 CAR-TCD 19 CAR-TCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19-targeted CAR-T cells (First Affiliated Hospital of Soochow University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-targeted CAR-T cells (First Affiliated Hospital of Soochow University).